(Alliance News) - AstraZeneca PLC on Wednesday announced drug approvals in Japan, including Lynparza for advanced ovarian cancer and Breztri Aerosphere for chronic obstructive pulmonary Aerosphere Read More
(Alliance News) - Stocks in London on Wednesday are set to build on the previous session's gains as traders await the latest decision from the US Federal Reserve in the wake of dovish comments Read More
(Alliance News) - An unremarkable start to the day for London stocks picked up mid-morning as dovish comments from European Central Bank President Mario Draghi boosted equities across Europe. - is Read More
(Alliance News) - Seemingly not wanting to be left out in a week that features policy meetings of the US Federal Reserve and the Bank of England, the head of the European Central Bank was the of a Read More
(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Ashtead, Read More
(Alliance News) - Stock prices in London opened flat on Tuesday, with Ashtead rising after strong annual results, helping the FTSE 100 to outperform other European indices.The UK Read More
(Alliance News) - AstraZeneca PLC on Saturday said its drug Calquence significantly prolonged the time patients lived without disease progression in chronic lymphocytic leukaemia.The drug - Read More
(Alliance News) - AstraZeneca PLC on Friday said its Lokelma drug was effective at treating hyperkalaemia in patients with end-stage rental disease who were on haemodialysis.Hyperkalaemia 3 Read More
LONDON (Alliance News) - Stocks in London were mixed Thursday at midday, with large- and mid-cap indices firmly in the green as investors anticipate a dovish outlook from Europe's central In a Read More
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rolls up Read More
LONDON (Alliance News) - AstraZeneca PLC on Thursday reported positive results from its trial of Calquence in patients with chronic lymphocytic leukaemia, a type of blood cancer.The FTSE of Read More
LONDON (Alliance News) - AstraZeneca PLC on Tuesday said its Lynparza drug produced a higher objective response rate than chemotherapy in advanced ovarian cancer and improved progression-free a of Read More
(Correcting that AstraZeneca presented two-year progression free survival data from its Polo trial not three-year overall survival data and that 10% of patients on placebo in the Lynparza trial no Read More
LONDON (Alliance News) - Stocks in London saw a mixed close on Monday despite trade tensions between the US, China and Mexico continuing to heat up, as well as disappointing manufacturing data.The Read More
LONDON (Alliance News) - AstraZeneca PLC on Sunday announced encouraging results from phase three trials of its cancer drugs Lynparza and Imfinzi.The drug maker presented three-year overall Read More
LONDON (Alliance News) - AstraZeneca PLC's Novel Start trial for its Symbicort Turbuhaler demonstrated a reduction in the rate of asthma attacks in patients with mild asthma compared to common Read More
LONDON (Alliance News) - AstraZeneca PLC said Thursday said it will present positive data from phase three trials of cancer drugs Lynparza and Imfinzi at the 2019 American Society of Clinical from Read More
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - Consolidated Airlines Group, up The Read More
LONDON (Alliance News) - London stocks were attempting to end a dire week on a brighter note, the FTSE 100 rising amid optimism the latest round of trade talks between the US and China on Friday a Read More
LONDON (Alliance News) - AstraZeneca PLC late Thursday said pooled analyses of phase three trials of roxadustat showed the anaemia drug only outperformed in patients who were new to dialysis in of Read More